Treatment-resistant depression (TRD) is a form of major depressive disorder in which symptoms persist despite trials of two or more antidepressant medications taken at adequate doses for sufficient durations. According to research published in the Journal of Clinical Psychiatry, approximately 30 percent of adults treated for depression meet the criteria for treatment resistance, affecting an estimated 2.8 million Americans each year.
If you have been living with depression that has not responded to standard antidepressants, you are not alone — and more importantly, effective options exist. At Elevate Psychiatry in Miami, our board-certified psychiatrists specialize in advanced, evidence-based treatments specifically designed for adults whose depression has not improved with conventional therapy.
The American Psychiatric Association defines TRD as a failure to achieve adequate response after at least two antidepressant trials of different pharmacological classes, each administered at therapeutic doses for a minimum of six to eight weeks. However, it is important to recognize that "treatment resistance" does not mean your depression is untreatable. In many cases, it means the right treatment has not yet been found.
Common reasons depression may appear treatment-resistant include misdiagnosis of the underlying condition (such as unrecognized bipolar disorder or a thyroid disorder), inadequate medication dosing or duration, co-occurring conditions like anxiety or substance use disorders, and pharmacogenomic factors that affect how your body metabolizes medications.
Treatment-resistant depression shares many symptoms with major depressive disorder, but certain patterns may indicate that your current treatment is not working effectively. Adults experiencing TRD often report persistent sadness or emptiness that does not lift despite medication adherence, chronic fatigue and low energy that interfere with daily responsibilities, difficulty concentrating or making decisions at work or home, withdrawal from social activities and relationships, changes in appetite or sleep patterns that medication has not addressed, and recurrent feelings of hopelessness about recovery.
Research from the National Institute of Mental Health suggests that adults with TRD experience significantly greater functional impairment, higher rates of disability, and increased healthcare utilization compared to those whose depression responds to first-line treatments. If these symptoms resonate with your experience, a comprehensive psychiatric evaluation can help determine whether a different treatment approach may be more effective.
Elevate Psychiatry offers a range of FDA-approved and evidence-based treatments that go beyond traditional antidepressants. Our Miami psychiatrists create individualized treatment plans that may incorporate one or more of the following approaches.
Transcranial magnetic stimulation is an FDA-cleared, non-invasive brain stimulation therapy that uses targeted magnetic pulses to activate nerve cells in brain regions associated with mood regulation. During a typical TMS session, a magnetic coil is placed against the scalp near the forehead, delivering focused pulses to the left dorsolateral prefrontal cortex — an area often underactive in people with depression.
Clinical trials have demonstrated that TMS achieves remission rates of approximately 30 to 35 percent in patients with treatment-resistant depression, with response rates exceeding 50 percent. Newer accelerated protocols, such as the Stanford Neuromodulation Therapy (SNT) protocol, have shown remission rates as high as 79 percent in initial studies published in the American Journal of Psychiatry. TMS is performed in-office without anesthesia, with sessions lasting approximately 20 to 40 minutes over four to six weeks.
Spravato (esketamine) is an FDA-approved nasal spray specifically indicated for treatment-resistant depression in adults. Unlike traditional antidepressants that target serotonin or norepinephrine, esketamine works on the glutamate system — the brain's most abundant excitatory neurotransmitter — to rapidly restore synaptic connections.
In clinical trials, 69.3 percent of adults with TRD experienced clinically meaningful improvement in symptoms when using Spravato in combination with an oral antidepressant, and 52.5 percent achieved full remission. In 2025, the FDA expanded its approval to allow esketamine as a monotherapy option. Treatment is administered under medical supervision at our Miami office, with patients monitored for approximately two hours after each session.
Ketamine therapy represents one of the most significant advances in psychiatric treatment over the past two decades. Originally developed as an anesthetic, ketamine has been shown to produce rapid antidepressant effects — often within hours rather than the weeks required by traditional medications. Research published in Biological Psychiatry indicates that a single ketamine infusion can reduce depressive symptoms within 24 hours in adults with TRD.
At Elevate Psychiatry, ketamine-assisted therapy is administered intravenously in a controlled clinical setting, allowing our psychiatrists to carefully titrate dosing and monitor your response in real time. This treatment is particularly beneficial for adults experiencing severe depression with suicidal ideation, as its rapid onset can provide critical relief while longer-term treatments take effect.
Electroconvulsive therapy remains one of the most effective treatments for severe, treatment-resistant depression, with response rates of 50 to 70 percent according to the American Psychiatric Association. Modern ECT is performed under general anesthesia and is significantly different from historical portrayals — it is safe, well-tolerated, and supported by decades of clinical evidence.
ECT works by delivering brief, controlled electrical pulses to the brain under anesthesia, triggering a therapeutic seizure that promotes neurochemical changes associated with mood improvement. Treatment typically involves two to three sessions per week for three to four weeks. ECT may be recommended when rapid symptom relief is essential or when other advanced treatments have not provided adequate improvement.
Before pursuing advanced interventions, our psychiatrists conduct a thorough review of your medication history to identify opportunities for optimization. This may include augmentation strategies (adding a second medication such as lithium, atypical antipsychotics, or thyroid hormone), switching to a different antidepressant class, or combining medications that work through complementary mechanisms.
Pharmacogenomic testing analyzes your DNA to determine how your body metabolizes specific medications. This information can reveal whether you are a rapid or poor metabolizer of certain antidepressants, helping your psychiatrist select medications that are more likely to be effective and less likely to cause side effects.
Elevate Psychiatry is uniquely positioned to treat adults with treatment-resistant depression in South Florida. Our practice offers a comprehensive range of advanced treatments — including TMS, Spravato, ketamine therapy, and ECT — under one roof, allowing for seamless coordination of your care without the need for multiple referrals.
Our board-certified psychiatrists bring specialized expertise in treatment-resistant conditions and work collaboratively with each patient to develop a personalized treatment plan based on clinical evidence, individual health history, and treatment goals. We accept most major insurance plans, including coverage for TMS and Spravato, and our team provides complimentary insurance verification to help you understand your benefits before beginning treatment.
With offices in Coconut Grove and Doral, plus virtual appointments available throughout Florida, accessing expert psychiatric care has never been more convenient. Same-week appointments are available for new patients, and Spanish-language services are offered at all locations.
Your initial psychiatric evaluation at Elevate Psychiatry is a comprehensive assessment designed to understand the full picture of your mental health. During this appointment, your psychiatrist will review your complete treatment history, including all medications tried, their dosages, duration, and your response to each. Your doctor will also assess for co-occurring conditions such as anxiety disorders, PTSD, substance use disorders, or medical conditions that may be contributing to treatment resistance.
Based on this evaluation, your psychiatrist will discuss the treatment options most likely to be effective for your specific situation and work with you to create a plan that aligns with your preferences, lifestyle, and goals. Many patients begin to notice improvement within weeks of starting a new treatment approach.
Treatment-resistant depression is defined as major depressive disorder that has not responded adequately to at least two different antidepressant medications taken at appropriate doses for at least six to eight weeks each. If you have tried multiple medications without significant improvement, you may have TRD.
While "cure" is not the standard clinical term, remission is absolutely achievable for many adults with TRD. Advanced treatments like TMS, Spravato, and ketamine therapy have demonstrated remission rates ranging from 30 to 79 percent in clinical studies. The key is finding the right treatment or combination of treatments for your unique situation.
TMS has demonstrated response rates exceeding 50 percent and remission rates of approximately 30 to 35 percent in adults with treatment-resistant depression. Newer accelerated protocols have shown even higher efficacy, with remission rates approaching 79 percent in certain studies.
Yes, most major insurance plans cover treatments for TRD, including TMS therapy and Spravato (esketamine). Coverage typically requires documentation that you have tried and not responded to at least two antidepressants. Elevate Psychiatry offers free insurance verification to help you understand your specific benefits.
Spravato (esketamine) is an FDA-approved nasal spray specifically indicated for treatment-resistant depression, administered in a clinical setting with a two-hour monitoring period. Ketamine is administered intravenously and, while widely used for TRD, is prescribed off-label for depression. Both target the glutamate system and can produce rapid antidepressant effects, often within hours to days.
Response times vary by treatment. Ketamine and Spravato can produce noticeable improvement within hours to days. TMS typically requires four to six weeks of daily sessions before full benefits are realized. ECT often shows improvement within the first week or two of treatment. Your psychiatrist will discuss expected timelines based on your chosen treatment plan.
Certain aspects of TRD care, such as initial evaluations, medication management, and follow-up appointments, can be conducted via telepsychiatry throughout Florida. However, treatments like TMS, Spravato, ketamine infusions, and ECT require in-person visits to our Miami offices. Elevate Psychiatry offers both virtual and in-person appointments to maximize convenience.
Living with depression that has not responded to treatment can feel exhausting and isolating, but effective options exist — and they may work differently than anything you have tried before. At Elevate Psychiatry, our Miami psychiatrists are committed to helping every adult patient find the path to meaningful improvement.
Schedule your consultation today. Call 305-908-1115 or book online at elevatepsychiatry.com to meet with a board-certified psychiatrist who specializes in treatment-resistant depression. Same-week appointments are available.
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Treatment-resistant depression requires individualized evaluation and care from a qualified psychiatrist. If you are experiencing a mental health emergency, please call 988 (Suicide and Crisis Lifeline) or go to your nearest emergency room.
